



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION

Clone ID	DM123
Target	PDL1
Synonyms	PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1
Host Species	Rabbit
Description	PE-conjugated Anti-PD-L1 antibody(DM123); Rabbit mAb
Delivery	Under Development
Uniprot ID	Q9NZQ7
IgG type	Rabbit IgG
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells; such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue; this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments; this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies; including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

